Active temporomandibular joint (TMJ) arthritis is a recognised manifestation in patients with juvenile idiopathic arthritis (JIA). This overlap requires an approach that accounts for the underlying systemic inflammatory condition.
Active TMJ arthritis occurring in the context of juvenile idiopathic arthritis. The American College of Rheumatology has issued specific guideline recommendations for this patient population.
Management in this setting involves a class of disease-modifying antirheumatic therapy directed at controlling the underlying inflammatory process. The full protocol specifies which agents apply, under what conditions, and how they are sequenced.
A guideline from the American College of Rheumatology includes recommendations for the treatment of active TMJ arthritis in patients with juvenile idiopathic arthritis.
Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) are recommended for patients with an inadequate response to or intolerance of NSAIDs and/or intra-articular glucocorticoids (this is the only strong recommendation).
View source ↗